The association between BMI and BSA–temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525

The association between BMI and BSA–temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525

Abstract Background Fearing increased myelotoxicity, many practitioners adjust the body surface area (BSA)-calculated doses in obese patients. Regarding temozolomide (TMZ), a prior study suggested men with a BSA >2 m2 may experience increased toxicity; however, surprisingly, the inverse observati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology practice 2019-12, Vol.6 (6), p.473-478
Hauptverfasser: Robins, H Ian, Eickhoff, Jens, Gilbert, Mark R, Armstrong, Terri S, Shi, Wenyin, De Groot, John F, Schultz, Christopher J, Hunter, Grant K, Valeinis, Egils, Roach, Mack, Youssef, Emad F, Souhami, Luis, Howard, Steve P, Lieberman, Frank S, Herman, James G, Zhang, Peixin, Mehta, Minesh P
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Fearing increased myelotoxicity, many practitioners adjust the body surface area (BSA)-calculated doses in obese patients. Regarding temozolomide (TMZ), a prior study suggested men with a BSA >2 m2 may experience increased toxicity; however, surprisingly, the inverse observation was noted in women, ie, BSA
ISSN:2054-2577
2054-2585
DOI:10.1093/nop/npz006